DS-3201b in Participants With Lymphomas

Inclusion Criteria

• •Has hematocytological or pathological diagnosis of non- Hodgkin's lymphoma (NHL)
• •Has relapsed from or is refractory to standard treatment or no standard treatment is available
• •Is the age of majority in their country (18 in the US and 20 in Japan) at the time of informed consent
• •Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• •Has at least one evaluable lesion site (not applicable for the DDI cohort)
• •Has preserved organ function based on baseline laboratory data at screening tests
• •If of reproductive potential, agrees to avoid harvesting ova or sperm, and to use a protocol-defined form of contraception or avoid intercourse, during and upon completion of the study, and for at least 3 months after the last dose of study drug
• •Tumor biopsy collections:
• •1. willing to provide archived or fresh tumor tissue samples that are sufficient for comprehensive genomic and/or proteomic analyses at baseline
• •2. \[US only\] willing to provide fresh on-treatment tumor biopsy if deemed acceptable risk by the investigator
• •\[Japan only\] fresh on-treatment tumor biopsy should be performed if deemed acceptable risk by the investigator
• •3. willing to provide optional fresh end-of-treatment biopsy
• •For ATL subjects:
• •Has a positive test result for human T-lymphotropic virus type I antibody
• •Has ATL subtype classified as acute, lymphomatous, or chronic with poor prognostic factor
• •Has diagnosis of relapse (including relapse after partial remission \[PR\]) or treatment-resistant ATL at the time of informed consent after prior treatment with at least 1 anti-cancer medication regimen